Smart Inhaler for Childhood Asthma

(IDD Trial)

Overseen By Alexis Deavenport-Saman, DrPH, MPH

Age: < 18

Sex: Any

Trial Phase: Academic

Sponsor: Children's Hospital Los Angeles

Must be taking: Inhaled corticosteroids

Disqualifiers: Limited life expectancy, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: 3

Duration: 8 weeks

30 Participants Needed

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial explores how smart inhalers can help children with intellectual and developmental disabilities (IDD) manage their asthma more effectively. Smart inhalers provide guidance and feedback to ensure correct medication use. The study aims to determine if these devices improve medication adherence and lung function in children with IDD. Children aged 10-17 with IDD and moderate-to-severe asthma may be suitable candidates for this trial. Participants will either receive standard asthma education or use the smart inhaler daily for eight weeks. As an unphased trial, this study offers a unique opportunity for participants to contribute to innovative research that could enhance asthma management for children with IDD.

Will I have to stop taking my current medications?

The trial does not specify if you need to stop taking your current medications. However, participants must use one of the specified inhalers like Ventolin HFA or Advair HFA, so you may need to continue using these if they are part of your current treatment.

What prior data suggests that the smart inhaler is safe for children with IDD?

Research shows that smart inhalers can help children remember to take their asthma medicine and maintain control over their asthma. These devices provide feedback on inhaler usage, which can improve medication adherence.

Although specific safety data for the smart inhalers themselves is lacking, the medicines they deliver have been studied and are generally safe when used correctly. Smart inhalers have been used successfully in children with asthma, proving helpful without causing harm.

No specific safety issues have been reported with smart inhalers, but it is important to use them as directed. Always consult a healthcare provider with any concerns about using a new device. ^{1 2 3 4 5}

Why are researchers excited about this trial?

The Smart Inhaler is unique because it integrates technology to monitor and improve asthma management in children. Unlike standard inhalers, which rely solely on patient adherence, the Smart Inhaler uses sensors to track usage and symptoms, providing real-time feedback and reminders. This innovation helps ensure consistent medication use, potentially reducing asthma attacks and improving overall control. Researchers are excited about this treatment because it empowers patients with data-driven insights, paving the way for more personalized and effective asthma care.

What evidence suggests that smart inhalers are effective for improving asthma management in children with IDD?

This trial will compare the use of a smart inhaler with standard asthma education. Studies have shown that smart inhalers can greatly improve asthma control and help children adhere to their treatment plans. Research indicates that these devices assist children in using their inhalers correctly by providing real-time guidance and feedback. One study found that this technology not only improved asthma management but also enhanced the quality of life for both children and their caregivers. Additionally, smart inhalers have filled important gaps in asthma care, making it easier for children to manage their condition effectively. While their effects on children with intellectual and developmental disabilities remain underexplored, the positive results in other children are encouraging. ^{1 6 7 8 9}

Who Is on the Research Team?

Larry Yin, MD, MSPH

Principal Investigator

Children's Hospital Los Angeles

Are You a Good Fit for This Trial?

This trial is for adolescents with intellectual and developmental disabilities (IDD), such as Autism Spectrum Disorder, who also have asthma. It's designed to help those who may struggle with using an inhaler correctly due to their IDD.

Inclusion Criteria

My child and I understand and can follow the study's requirements.

Not involved in other studies using digital inhalers

I am between 10 and 17 years old.

Exclusion Criteria

All candidates meeting any of the exclusion criteria at baseline will be excluded from study participation:

Health status or any clinical conditions: Limited life expectancy, co-existing disease or other characteristics that precludes appropriate diagnosis, treatment, or follow-up in the trial

Inability or unwillingness of individual or legal guardian/representative to give written informed consent

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants in the intervention group use smart inhalers daily for 8 weeks, while the control group receives standard asthma education

8 weeks

3 visits (in-person), each scheduled four weeks apart

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

• Smart Inhaler

Trial Overview

The study tests if smart inhalers can help young people with IDD use their asthma medication more effectively. The smart inhaler provides guidance and feedback on technique, aiming to improve correct usage and lung function.

How Is the Trial Designed?

Group I: Intervention Experimental Treatment 1 Intervention

Uses smart inhaler daily for 8 weeks

Group II: Control Active Control 1 Intervention

Standard asthma education arm

Who Is Running the Clinical Trial?

Children's Hospital Los Angeles

Lead Sponsor

Trials

257

Recruited

5,075,000+

Published Research Related to This Trial

This scoping review aims to explore how smart devices can be used to improve asthma management in children and young adults, particularly focusing on low-income and culturally diverse populations who face higher asthma-related health challenges.

The review will analyze a wide range of studies involving participants aged 0 to 26 with asthma, using multiple databases to ensure comprehensive coverage of existing literature and to identify potential gaps in research.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Smart devices for the management of pediatric asthma: a scoping review protocol. Betz, CL., Lewinter, K., Kysh, L., et al.[2020]

The study involved 1306 quality control tests of an electronic monitoring device for asthma inhalers, showing a high reliability rate of 84% for pre-issue tests and 87% for return tests, although some devices had issues with under-recording.

Children using the device with reminder features reported significantly higher acceptability scores compared to those without reminders, with over 90% finding the device easy to use, indicating strong potential for improving asthma management in this age group.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Electronic adherence monitoring device performance and patient acceptability: a randomized control trial. Chan, AHY., Stewart, AW., Harrison, J., et al.[2018]

The use of a smart nebulizing device significantly improved adherence to inhaled corticosteroids (ICS) in children under 5 years old, with adherence rates of 86.67% compared to 62.86% in the conventional nebulization group after 12 weeks.

Children using the smart nebulizer experienced fewer emergency visits and lower rates of respiratory infections and antibiotic use, indicating that this technology not only enhances medication adherence but also improves overall health outcomes.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Short-term effect of a smart nebulizing device on adherence to inhaled corticosteroid therapy in Asthma Predictive Index-positive wheezing children. Zhou, Y., Lu, Y., Zhu, H., et al.[2022]

The Funhaler, a new small volume spacer device, significantly improved the success rate of administering asthma medication to children, with 22 out of 30 parents reporting consistent success compared to only 3 out of 30 with their existing device.

Parents and children showed better adherence and a more positive attitude towards asthma treatment when using the Funhaler, indicating its potential to enhance compliance and satisfaction in managing asthma in young children.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

A new asthma spacer device to improve compliance in children: a pilot study. Chaney, G., Clements, B., Landau, L., et al.[2006]

A systematic review of 46 studies on pediatric asthma medications revealed that inhaled corticosteroids (ICS) are associated with 174 adverse drug events (ADE), including potential issues like adrenal and growth suppression.

Serious adverse drug events were rare, occurring in 0.9-6% of cases, and there were no confirmed deaths in pediatric patients, although methodological concerns were noted regarding the identification and assessment of ADE in the studies reviewed.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

A systematic review of adverse drug events associated with administration of common asthma medications in children. Leung, JS., Johnson, DW., Sperou, AJ., et al.[2022]

The Single Inhaler Therapy (SIT) or Symbicort Maintenance and Reliever Therapy (SMART) approach has shown safety and efficacy in adults with asthma, and preliminary cases suggest it may also benefit children and adolescents, with two out of three cases demonstrating clear clinical improvement.

While SIT could help reduce compliance issues in managing asthma among younger patients, further studies are necessary to confirm its effectiveness and safety across different asthma phenotypes in this age group.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

[Formoterol-budesonide combination for maintenance and relief in children and adolescents with asthma]. de Bilderling, G., Smal, D., Bradatan, E.[2018]

In a retrospective study of 31 children with severe asthma, using a smart nebulizer to deliver high doses of inhaled corticosteroids significantly reduced the rate of asthma exacerbations requiring oral corticosteroids, from a median of 2 to 0.5 per year (p=0.021).

Hospital admissions also decreased significantly from a median of 1 to 0 after one year of treatment (p=0.028), indicating improved management of severe asthma, although lung function measures did not show significant improvement.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Small airways targeted treatment with smart nebulizer technology could improve severe asthma in children: a retrospective analysis. van den Bosch, WB., Kloosterman, SF., Andrinopoulou, ER., et al.[2022]

A comprehensive analysis of 372,345 spontaneous reports from 2011 to 2017 identified 385 different safety signals related to asthma medications in children, with a notable focus on psychiatric events, highlighting the importance of monitoring these drugs in the pediatric population.

The study uncovered new safety signals, such as herpes viral infections linked to omalizumab and hypertrichosis associated with budesonide, emphasizing that age stratification is crucial for detecting unique risks in children that may not be evident in the broader population.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Exploratory Study of Signals for Asthma Drugs in Children, Using the EudraVigilance Database of Spontaneous Reports. Baan, EJ., de Smet, VA., Hoeve, CE., et al.[2021]

A review of 326 spontaneous adverse drug reaction reports for asthma medications in children revealed that approximately 85% of these reports were serious, including six fatal cases, highlighting significant safety concerns.

The most commonly reported adverse reactions were psychiatric disorders (13%), respiratory issues (10%), and skin disorders (9%), with budesonide, salbutamol, and fluticasone being the medications with the highest number of reported ADRs.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Paediatric adverse drug reactions following use of asthma medications in Europe from 2007 to 2011. Aagaard, L., Hansen, EH.[2021]

A novel device that records inhalation patterns aims to improve asthma control in children aged 6 to 18 by providing immediate feedback on inhalation technique and adherence, potentially reducing asthma exacerbations.

The study will include 68 children with uncontrolled asthma and will assess the effectiveness of this feedback through a randomized controlled trial, measuring outcomes like lung function and asthma control scores over a total of 16 weeks.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Does immediate smart feedback on therapy adherence and inhalation technique improve asthma control in children with uncontrolled asthma? A study protocol of the IMAGINE I study. Sportel, ET., Oude Wolcherink, MJ., van der Palen, J., et al.[2021]

Inhalation therapy for childhood asthma is both safe and effective, offering benefits such as low doses, rapid effects, and a wide therapeutic range.

Optimal asthma treatment in children can be achieved with the right selection of inhalation devices and consistent practical instructions for use.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

[Inhalation therapy in children with asthma]. de Jongste, JC., van Essen-Zandvliet, EE., Brackel, HJ., et al.[2008]

Citations

1.

sciencedirect.com

sciencedirect.com/science/article/pii/S152605422500079X

Smart inhalers in paediatric asthma: bridging the gap ...

This adaptive model significantly improved both adherence and asthma control, demonstrating the value of asynchronous monitoring not only for ...

2.

pubmed.ncbi.nlm.nih.gov

pubmed.ncbi.nlm.nih.gov/41047308/

Smart inhalers in paediatric asthma: bridging the gap ...

Smart inhaler systems represent a major opportunity to transform paediatric asthma care by potentially addressing three fundamental problems ...

3.

bmjopenrespres.bmj.com

bmjopenrespres.bmj.com/content/9/1/e001400

Effectiveness, usability and acceptability of a smart inhaler ...

This study aims to investigate the effectiveness of a smart inhaler asthma self-management programme on medication adherence and clinical outcomes in adults ...

4.

luriechildrens.org

luriechildrens.org/en/news-stories/smart-asthma-inhaler-sensors-improve-pediatric-asthma-control/

“Smart” Asthma Inhaler Sensors Improve Pediatric ...

The trial found that using sensor-based asthma inhalers may improve control of the condition and improve the quality of life for caregivers.

5.

tandfonline.com

tandfonline.com/doi/full/10.1080/17476348.2024.2380067

Current technological advancement in asthma care

The authors reported that the participants using the digital inhaler system had better asthma control compared to patients on standard management. Adherence to ...

6.

pmc.ncbi.nlm.nih.gov

pmc.ncbi.nlm.nih.gov/articles/PMC10198788/

Anticipated barriers and facilitators for implementing smart ...

Smart inhalers are electronic monitoring devices which are promising in increasing medication adherence and maintaining asthma control.

7.

answers.childrenshospital.org

answers.childrenshospital.org/smart-asthma-inhaler/

SMART asthma care with one inhaler, not two

Under new SMART asthma guidelines, some patients can use the same inhaler for prevention and rescue therapy. Dr. Jonathan Gaffin explains.

8.

jaci-inpractice.org

jaci-inpractice.org/article/S2213-2198(21)01128-4/fulltext

A Practical Guide to Implementing SMART in Asthma ...

The efficacy and safety of SMART with budesonide-formoterol and beclometasone-formoterol have been confirmed, but other ICS–long-acting ...

9.

withpower.com

withpower.com/trial/smart-inhaler-for-childhood-asthma-6047d

Smart Inhaler for Childhood Asthma (IDD Trial)

Is the Smart Inhaler safe for children with asthma? There is no specific safety data available for the Smart Inhaler itself, but studies on asthma medications ...